Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
1(33%)
Results Posted
200%(2 trials)
Terminated
1(33%)

Phase Distribution

Ph phase_3
2
67%
Ph early_phase_1
1
33%

Phase Distribution

1

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Early Phase 1First-in-human
1(33.3%)
Phase 3Large-scale testing
2(66.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(1)
Terminated(1)

Detailed Status

Completed1
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (33.3%)
Phase 32 (66.7%)

Trials by Status

completed133%
recruiting133%
terminated133%

Recent Activity

1 active trials
Showing 3 of 3
recruitingearly_phase_1

Metformin for Premature Infants With Bronchopulmonary Dysplasia

NCT07120971
terminatedphase_3

A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)

NCT01477853
completedphase_3

A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

NCT00374907

Clinical Trials (3)

Showing 3 of 3 trials
NCT07120971Early Phase 1

Metformin for Premature Infants With Bronchopulmonary Dysplasia

Recruiting
NCT01477853Phase 3

A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)

Terminated
NCT00374907Phase 3

A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

Completed

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3